{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:49:35Z","timestamp":1782805775215,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An important factor in the universal failure in phase III trials in mild to moderate Alzheimer\u2019s disease in the past decade is the lack of phase II clinical data prior to entering phase III, with common reliance on biomarker results alone. Conduction of two learn-confirm cycles according to the Sheiner model would allow go\/no-go decision making to include reliable clinical efficacy data prior to conducting phase III and would likely bring the rate of late stage failure more into line with that of other neurological indications. In studies in earlier disease stages, combined phase IIB\/III adaptive approaches merit consideration in view of the long timelines of each study, though advantages and disadvantages of this approach versus the classical development pathway still need careful assessment.<\/jats:p>","DOI":"10.1186\/s13195-015-0153-y","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T04:05:16Z","timestamp":1445832316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The need for thorough phase II studies in medicines development for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"7","author":[{"given":"Julian A.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"153_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstoff T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimer\u2019s Res Ther. 2014;6:37.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"153_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Internal Med. 2014;275:251\u201328.","journal-title":"J Internal Med"},{"key":"153_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"1","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;1:40\u201351.","journal-title":"Nat Biotechnol"},{"key":"153_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2174\/156720510793499075","volume":"7","author":"RE Becker","year":"2010","unstructured":"Becker RE, Greig NH. Why so few drugs for Alzheimer\u2019s disease? Are methods failing drugs? Curr Alzheimer Res. 2010;7:642\u201351.","journal-title":"Curr Alzheimer Res"},{"key":"153_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76:185\u2013205.","journal-title":"Ann Neurol"},{"key":"153_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/pst.1633","volume":"13","author":"C Chuang-Stein","year":"2014","unstructured":"Chuang-Stein C, Kirby S. The shrinking or disappearing observed treatment effect. Pharmaceut Stat. 2014;13:277\u201380.","journal-title":"Pharmaceut Stat"},{"key":"153_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","volume":"61","author":"LB Sheiner","year":"1997","unstructured":"Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275\u201391.","journal-title":"Clin Pharmacol Ther"},{"key":"153_CR8","first-page":"293","volume":"7","author":"SL Rogers","year":"1996","unstructured":"Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996;7:293\u2013303.","journal-title":"Dementia"},{"key":"153_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","volume":"158","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer\u2019s disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021\u201331.","journal-title":"Arch Intern Med"},{"key":"153_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group. Neurology. 1998;50:136\u201345.","journal-title":"Neurology"},{"key":"153_CR11","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer\u2019s disease a randomised controlled trial. JAMA. 2009;302:2557\u201364.","journal-title":"JAMA"},{"key":"153_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","volume":"5","author":"LS Schneider","year":"2009","unstructured":"Schneider LS, Sano M. Current Alzheimer\u2019s disease clinical trials: methods and placebo outcomes. Alzheimer\u2019s Dement. 2009;5:388\u201397.","journal-title":"Alzheimer\u2019s Dement"},{"key":"153_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"153_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jalz.2014.04.450","volume":"10","author":"J Cummings","year":"2014","unstructured":"Cummings J, Cho W, Ward N, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomised, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2014;10:275. http:\/\/www.alzheimersanddementia.com\/article\/S1552-5260%2814%2900578-0\/abstract.","journal-title":"Alzheimer\u2019s Dement"},{"key":"153_CR15","unstructured":"Food and Drugs Administration (FDA). Guidance for Industry (draft): Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338287.pdf."},{"key":"153_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000381736","volume":"15","author":"J Sevigny","year":"2015","unstructured":"Sevigny J, Chiao P, Williams L, Miao C, O\u2019Gorman J. Randomised, double-blind, phase Ib study of BIIB037, an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer\u2019s disease. In: Mechanisms, Clinical Strategies and Promising Treatments of Neurodegenerative Diseases. 12th International Conference on Alzheimer\u2019s and Parkinson\u2019s diseases, Nice France, March 18\u201322, 2015. Neurodegener Dis. 2015;15:311. doi:10.1159\/000381736.","journal-title":"Neurodegener Dis"},{"key":"153_CR17","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/sim.5346","volume":"31","author":"TL Lai","year":"2012","unstructured":"Lai TL, Lavori PW, Shih MC. Sequential design of phase II-III cancer trials. Stat Med. 2012;31:1944\u201360.","journal-title":"Stat Med"},{"key":"153_CR18","unstructured":"Gray JA. Medicines Development in Alzheimer\u2019s disease, Supplement to Gray\u2019s Medicines Development. 2015. http:\/\/www.graybook.net\/."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-015-0153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-015-0153-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-015-0153-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-015-0153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T04:28:04Z","timestamp":1643603284000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-015-0153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1186\/s13195-015-0153-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]},"assertion":[{"value":"26 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"67"}}